Stockscreener 앱 받기
0.631
1.59%
-0.0102
시간 외 거래:
.65
0.019
+3.01%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Reports Pelareorep Liver Cancer Research Findings - grafa.com
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com - Investing.com South Africa
Oncolytics reports pelareorep data in liver cancer study - Investing.com
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy - GlobeNewswire
Oncolytics Biotech Inc (ONCY) Stock Price Target & Forecast - TradingKey
Form 8K Oncolytics Biotech Inc. For: 28 September By Investing.com - Investing.com Nigeria
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech (ONCY) Advances Clinical Trial for Metastatic Colorectal Cancer Pelareorep Treatment - GuruFocus
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
Oncolytics reports accelerated enrollment, expects Part A interim REO 033 data by year-end 2026 - TradingView
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 - Yahoo Finance
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2%Time to Sell? - MarketBeat
ONCY Q3 2025 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Misses EPS EstimateEarnings Cycle Outlook - dars.gov.et
Oncolytics Biotech stock lacks a fresh catalyst and stays near $0.77 - AD HOC NEWS
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets - Yahoo Finance
Oncolytics Biotech Stock Price Forecast. Should You Buy ONCY? - StockInvest.us
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus
Oncolytics reports preclinical data on pelareorep with RAS inhibitor - investing.com
Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India
An experimental cancer treatment combination reduced tumor growth in early tests - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC - Yahoo Finance
Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - finance.yahoo.com
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria
Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com
Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada
Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView
Oncolytics may seek accelerated approval using tumor response data - Stock Titan
Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn
ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn
Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
0.05%
0.82%
자본화:
|
볼륨(24시간):